Protagonist Therapeutics (NASDAQ:PTGX) versus NeuroSense Therapeutics (NASDAQ:NRSN) Critical Contrast

Protagonist Therapeutics (NASDAQ:PTGX) and NeuroSense Therapeutics (NASDAQ:NRSN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Profitability

This table compares Protagonist Therapeutics and NeuroSense Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
NeuroSense Therapeutics	N/A	N/A	N/A

Risk and Volatility

Protagonist Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Protagonist Therapeutics and NeuroSense Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0	2	15	1	2.94
NeuroSense Therapeutics	1	1	2	1	2.60

Protagonist Therapeutics presently has a consensus target price of $140.53, suggesting a potential downside of 7.24%. NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 1,978.24%. Given NeuroSense Therapeutics’ higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Protagonist Therapeutics.

Earnings & Valuation

This table compares Protagonist Therapeutics and NeuroSense Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$281.99 million	34.76	-$130.15 million	$1.03	147.09
NeuroSense Therapeutics	N/A	N/A	-$11.12 million	($0.54)	-0.76

NeuroSense Therapeutics has lower revenue, but higher earnings than Protagonist Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Protagonist Therapeutics beats NeuroSense Therapeutics on 10 of the 13 factors compared between the two stocks.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson’s disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.